|
1
|
Shi Y, Yan T, Lu X, Li K, Nie Y, Jiao C, Sun H, Li T, Li X, Han D. Phloridzin Reveals New Treatment Strategies for Liver Fibrosis. Pharmaceuticals (Basel) 2022; 15:ph15070896. [PMID: 35890194 PMCID: PMC9321461 DOI: 10.3390/ph15070896] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/13/2022] [Accepted: 07/14/2022] [Indexed: 11/16/2022] Open
Abstract
Liver fibrosis is an urgent public health problem which is difficult to resolve. However, various drugs for the treatment of liver fibrosis in clinical practice have their own problems during use. In this study, we used phloridzin to treat hepatic fibrosis in the CCl4-induced C57/BL6N mouse model, which was extracted from lychee core, a traditional Chinese medicine. The therapeutic effect was evaluated by biochemical index detections and ultrasound detection. Furthermore, in order to determine the mechanism of phloridzin in the treatment of liver fibrosis, we performed high-throughput sequencing of mRNA and lncRNA in different groups of liver tissues. The results showed that compared with the model group, the phloridzin-treated groups revealed a significant decrease in collagen deposition and decreased levels of serum alanine aminotransferase, aspartate aminotransferase, laminin, and hyaluronic acid. GO and KEGG pathway enrichment analysis of the differential mRNAs was performed and revealed that phloridzin mainly affects cell ferroptosis. Gene co-expression analysis showed that the target genes of lncRNA were obvious in cell components such as focal adhesions, intercellular adhesion, and cell–substrate junctions and in metabolic pathways such as carbon metabolism. These results showed that phloridizin can effectively treat liver fibrosis, and the mechanism may involve ferroptosis, carbon metabolism, and related changes in biomechanics.
Collapse
Affiliation(s)
- Yahong Shi
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; (Y.S.); (T.Y.); (X.L.); (K.L.); (H.S.); (T.L.)
- National Center for Nanoscience and Technology, Beijing 100190, China;
| | - Tun Yan
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; (Y.S.); (T.Y.); (X.L.); (K.L.); (H.S.); (T.L.)
- National Center for Nanoscience and Technology, Beijing 100190, China;
- College of Pharmacy, Baotou Medical College, Baotou 014042, China
| | - Xi Lu
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; (Y.S.); (T.Y.); (X.L.); (K.L.); (H.S.); (T.L.)
- National Center for Nanoscience and Technology, Beijing 100190, China;
| | - Kai Li
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; (Y.S.); (T.Y.); (X.L.); (K.L.); (H.S.); (T.L.)
- National Center for Nanoscience and Technology, Beijing 100190, China;
| | - Yifeng Nie
- National Center for Nanoscience and Technology, Beijing 100190, China;
| | - Chuqiao Jiao
- Beijing City International School, Beijing 100022, China;
| | - Huizhen Sun
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; (Y.S.); (T.Y.); (X.L.); (K.L.); (H.S.); (T.L.)
- National Center for Nanoscience and Technology, Beijing 100190, China;
| | - Tingting Li
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China; (Y.S.); (T.Y.); (X.L.); (K.L.); (H.S.); (T.L.)
- National Center for Nanoscience and Technology, Beijing 100190, China;
| | - Xiang Li
- National Center for Nanoscience and Technology, Beijing 100190, China;
- Correspondence: (X.L.); (D.H.); Tel.: +86-82545630 (X.L.); +86-82545568 (D.H.)
| | - Dong Han
- National Center for Nanoscience and Technology, Beijing 100190, China;
- Correspondence: (X.L.); (D.H.); Tel.: +86-82545630 (X.L.); +86-82545568 (D.H.)
| |
Collapse
|